# A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

Source: https://onco.cc/trials/nct07255664/  
OnCo record `nct07255664` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Mesna in colorectal cancer and prostate cancer, run by CuraCell TX AB, now recruiting.

## Summary

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC is a phase 1/2 interventional study registered as NCT07255664 by CuraCell TX AB, with 12 participants planned, started 2025-11-13 and due to reach its primary completion in 2027-04. Interventions recorded: CC-38, Pembrolizumab, Cyclophosphamid, Interleukin-2, Uromitexan. Conditions listed: Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07255664
- Phase: 1/2
- Setting: A FIH, Phase I/IIa, Open-label Trial Assessing Safety, Tolerability, and Feasibility of Repeated Administrations of a Novel Autologous TIL-based Immunotherapy in Patients With Metastatic Colorectal or Prostate Cancer
- Sponsor: CuraCell TX AB
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT07255664: https://clinicaltrials.gov/study/NCT07255664

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Mesna](https://onco.cc/drugs/mesna/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct07255664.json